Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
CRISPR Therapeutics AG
CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
IPO Date: October 19, 2016
Sector: Healthcare
Industry: Biotech
Market Cap: $3.27B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.63 | 2.81%
Avg Daily Range (30 D): $1.16 | 3.23%
Avg Daily Range (90 D): $1.07 | 2.67%
Institutional Daily Volume
Avg Daily Volume: 1.1M
Avg Daily Volume (30 D): 1.93M
Avg Daily Volume (90 D): 1.96M
Trade Size
Avg Trade Size (Sh.): 64
Avg Trade Size (Sh.) (30 D): 63
Avg Trade Size (Sh.) (90 D): 65
Institutional Trades
Total Inst.Trades: 5,187
Avg Inst. Trade: $2.73M
Avg Inst. Trade (30 D): $2.51M
Avg Inst. Trade (90 D): $2.3M
Avg Inst. Trade Volume: .04M
Avg Inst. Trades (Per Day): 3
Market Closing Trades
Avg Closing Trade: $4.87M
Avg Closing Trade (30 D): $5.45M
Avg Closing Trade (90 D): $5.41M
Avg Closing Volume: 72.98K
       
News
Apr 20, 2025 @ 1:15 PM
5 Monster Stocks -- Such as Coupang -- to Hold for...
Source: Selena Maranjian
Apr 11, 2025 @ 7:45 AM
Could CRISPR Therapeutics Become the Next Vertex P...
Source: Adria Cimino
Apr 8, 2025 @ 1:45 PM
Is Vertex Pharmaceuticals Stock a Buy?
Source: Dan Victor
Apr 7, 2025 @ 12:09 PM
4 Beaten-Down Stocks That Could Skyrocket by 50% t...
Source: Prosper Junior Bakiny
Apr 7, 2025 @ 11:30 AM
Cathie Wood Goes Bargain Hunting: 3 Stocks She Jus...
Source: Rick Munarriz
Financials
  TTM Q4 2024 FY 2024
Basic EPS $-4.34 $-.42 $-4.34
Diluted EPS $-4.34 $-.42 $-4.34
Revenue $ 37.31M $ 35.69M $ 37.31M
Gross Profit $ $ $
Net Income / Loss $ -366.25M $ -37.31M $ -366.25M
Operating Income / Loss $ -466.57M $ -64.59M $ -466.57M
Cost of Revenue $ $ $
Net Cash Flow $ -91.27M $ 72.67M $ -91.27M
PE Ratio